NEW YORK, Jan. 30 - The Harvard Institute of Proteomics said it plans to use BD Biosciences machines to create thousands of gene clones.
In the partnership, Harvard researchers will use only BD Bioscience's gene cloning and expression system, called BD Creator, and have access to the system's platform technology. The company will also support the research.
In return, Harvard researchers will validate and help develop the system. BD Bioscience will retain commercial rights to the genes cloned and make them available for genetic function experiments, the company said.
Financial terms of the collaboration, announced on Tuesday, were not disclosed.
The BD Creator uses recombination technology to transfer genes into expression vectors. According to the company, it can be used simultaneously to create dozens of gene clones.
The Harvard Institute of Proteomics is part of the Harvard Medical School. Last spring, the institute announced plans to build FLEXGene, a repository of full-length cDNA clones. At the time, researchers set the goal of sequencing 100,000 clones within three years at a cost of roughly $100 million.
In this effort, it has been using Invitrogen's Gateway recombinatorial cloning technology. HIP director Josh LaBaer has recently said that the group can currently produce about 500 clones a week.
BD Biosciences is a division of Becton, Dickinson.